Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy Periactin (Cyproheptadine).
The 4mg generic tablet formulation is approved in the same indications as its reference product, including the treatment of allergy symptoms such as hives, sneezing, and itchy or watery eyes or nose.
Beximco said that the total market in the US for the mediciation was around $16 million in 2018.
